Loading clinical trials...

Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years | Clinical Trials | Clareo Health

COMPLETED

Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years

Intensive Hospital-based Adverse Drug Reaction Monitoring Study On Patients Treated By Qingkailing Injection In The Next Two Years

NCT01764204•China Academy of Chinese Medical Sciences

View on ClinicalTrials.gov

Summary

To highlight the incidence of adverse reactions of Qingkailing Injection.

Eligibility

Age

1 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•all the patients treated by Qingkailing Injection in the certain centers(hospitals) in the next 2 years.
•in accordance with ethics requirements.

Exclusion Criteria

•none.

Locations (48)

National Defense University Hospital of People's Liberation Army

Beijing, Beijing Municipality, China

Ren'ai Hospital

Shenzhen, Guangdong, China

Chinese Medicine Hospital of Deqing County

Zhaoqing, Guangdong, China

Chinese Medicine Hospital of Gaoyang County

Baoding, Hebei, China

Gaoyang County Hospital

Baoding, Hebei, China

The Third People's Hospital of Xiong County

Baoding, Hebei, China

Chinese Medicine Hospital of Xiong County

Baoding, Hebei, China

Chinese Medicine Hospital of Tang County

Baoding, Hebei, China

People's Hospital of Tang County

Baoding, Hebei, China

Chinese Medicine Hospital of Handan City

Handan, Hebei, China

Key Dates

Start Date

January 1, 2013

Primary Completion Date

December 1, 2017

Completion Date

January 1, 2018

Last Updated

February 19, 2018

Enrollment

30,840

ACTUAL participants

Conditions

Adverse Drug EventsAdverse Drug Reactions

Interventions

Qingkailing Injection

DRUG

The Geriatric Emergency Department Pharmacologic Harm Prevention Project

NCT07216846

FallFall Accident+4 more

View study

NOT_YET_RECRUITING

The Critical Care Recovery Program: Use of a Structured Clinic Visit to Reduce Adverse Drug Events in ICU Survivors

NCT06723860

Post Intensive Care Syndrome (PICS)Polypharmacy+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 19, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years

Inclusion Criteria

Exclusion Criteria

The Geriatric Emergency Department Pharmacologic Harm Prevention Project

The Critical Care Recovery Program: Use of a Structured Clinic Visit to Reduce Adverse Drug Events in ICU Survivors

Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.

Drug-Related Problems : Focus on Age and Diabetes

The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial

The Influence of CYP2C19 Polymorphisms on the Safety and Efficacy of Voriconazole